Literature DB >> 26416855

Efficacy of humanized high-dose meropenem, cefepime, and levofloxacin against Enterobacteriaceae isolates producing Verona integron-encoded metallo-β-lactamase (VIM) in a murine thigh infection model.

Islam M Ghazi1, Jared L Crandon1, Emil P Lesho2, Patrick McGann2, David P Nicolau3.   

Abstract

We aimed to describe the in vivo activity of humanized pharmacokinetic exposures of meropenem and comparators against Verona integron-encoded metallo-β-lactamase (MBL) (VIM)-producing Enterobacteriaceae in a murine model. Levofloxacin activity was predicted by its MIC, and cefepime activity displayed variability, whereas meropenem produced a >1 log CFU reduction against all isolates despite high MICs indicative of resistance. Our results suggest that despite in vitro resistance, high-dose meropenem may be a possible option against infections caused by Enterobacteriaceae producing MBL-type carbapenemases.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26416855      PMCID： PMC4604359          DOI： 10.1128/AAC.00794-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Contribution of β-lactamases and porin proteins OmpK35 and OmpK36 to carbapenem resistance in clinical isolates of KPC-2-producing Klebsiella pneumoniae.

Authors:  Ying Zhang; Xiaofei Jiang; Yanyan Wang; Gang Li; Yueru Tian; Hong Liu; Fuqi Ai; Yiming Ma; Bei Wang; Feiyi Ruan; Kumar Rajakumar
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191

2.  Unexpected in vivo activity of ceftazidime alone and in combination with avibactam against New Delhi metallo-β-lactamase-producing Enterobacteriaceae in a murine thigh infection model.

Authors:  Shawn H MacVane; Jared L Crandon; Wright W Nichols; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2014-09-15       Impact factor: 5.191

3.  In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae.

Authors:  Jared L Crandon; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2015-02-23       Impact factor: 5.191

4.  Impact of various conditions on the efficacy of dual carbapenem therapy against KPC-producing Klebsiella pneumoniae.

Authors:  Dora E Wiskirchen; Jared L Crandon; David P Nicolau
Journal:  Int J Antimicrob Agents       Date:  2013-04-21       Impact factor: 5.283

5.  Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.

Authors:  Anne Marie Queenan; Wenchi Shang; Robert Flamm; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

6.  Efficacy of doripenem and ertapenem against KPC-2-producing and non-KPC-producing Klebsiella pneumoniae with similar MICs.

Authors:  Mao Hagihara; Jared L Crandon; Carl Urban; David P Nicolau
Journal:  J Antimicrob Chemother       Date:  2013-03-08       Impact factor: 5.790

Review 7.  Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment.

Authors:  Mark E Rupp; Paul D Fey
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  In vivo efficacy of human simulated regimens of carbapenems and comparator agents against NDM-1-producing Enterobacteriaceae.

Authors:  Dora E Wiskirchen; Patrice Nordmann; Jared L Crandon; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2013-12-30       Impact factor: 5.191

9.  Efficacy of humanized carbapenem and ceftazidime regimens against Enterobacteriaceae producing OXA-48 carbapenemase in a murine infection model.

Authors:  Dora E Wiskirchen; Patrice Nordmann; Jared L Crandon; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2013-12-30       Impact factor: 5.191

10.  Vital signs: carbapenem-resistant Enterobacteriaceae.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-03-08       Impact factor: 17.586
View more
  8 in total

1.  Determinants for persistence of Pseudomonas aeruginosa in hospitals: interplay between resistance, virulence and biofilm formation.

Authors:  S J Kaiser; N T Mutters; A DeRosa; C Ewers; U Frank; F Günther
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-10-12       Impact factor: 3.267

Review 2.  Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.

Authors:  Mordechai Grupper; Joseph L Kuti; David P Nicolau
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

3.  Translational Efficacy of Humanized Exposures of Cefepime, Ertapenem, and Levofloxacin against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Complicated Urinary Tract Infection.

Authors:  Marguerite L Monogue; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

Review 4.  Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline.

Authors:  Sara E Boyd; David M Livermore; David C Hooper; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

5.  In Vivo Efficacy of Plazomicin Alone or in Combination with Meropenem or Tigecycline against Enterobacteriaceae Isolates Exhibiting Various Resistance Mechanisms in an Immunocompetent Murine Septicemia Model.

Authors:  Kamilia Abdelraouf; Aryun Kim; Kevin M Krause; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

6.  Variability in Zinc Concentration among Mueller-Hinton Broth Brands: Impact on Antimicrobial Susceptibility Testing of Metallo-β-Lactamase-Producing Enterobacteriaceae.

Authors:  Anastasia Bilinskaya; Douglas J Buckheit; Michael Gnoinski; Tomefa E Asempa; David P Nicolau
Journal:  J Clin Microbiol       Date:  2020-11-18       Impact factor: 5.948

7.  Polymorphisms of Gene Cassette Promoters of the Class 1 Integron in Clinical Proteus Isolates.

Authors:  Linlin Xiao; Xiaotong Wang; Nana Kong; Mei Cao; Long Zhang; Quhao Wei; Weiwei Liu
Journal:  Front Microbiol       Date:  2019-04-24       Impact factor: 5.640

8.  In vivo efficacy of humanized high dose meropenem and comparators against Pseudomonas aeruginosa isolates producing verona integron-encoded metallo-β-lactamase (VIM).

Authors:  Islam M Ghazi; Jared L Crandon; Emil P Lesho; Patrick McGann; David P Nicolau
Journal:  Heliyon       Date:  2016-06-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.